February 29, 2016 / 2:56 PM / 2 years ago

BUZZ-Valeant Pharmaceuticals: Results delayed

** Canadian drugmaker’s U.S.-listed shares down 7 pct at $74.92; Toronto-traded stock down 8 pct at C$101.01

** Postpones Q4 results and withdraws its prior 2016 financial outlook

** Says it will release preliminary 2015 results and a 2016 outlook “in the near term”

** Says CEO Michael Pearson to return from medical leave, effective immediately

** TD Securities cuts its rating to “hold” from “buy” to reflect the reduced visibility into the FY16 outlook, cuts PT to $110 from $155

** Canaccord Genuity cuts PT to $125 from $170

** 13 of 24 brokerages rate the stock “buy” or higher, 9 “hold” and 2 “sell” or lower; their median PT is $152.50

** Up to Friday’s close, U.S. stock had fallen 60 pct in the past 12 months

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below